Boomerang runs a clinical trial for ulcerative colitis that evaluates a non‑drug neurostimulation device aimed at reducing bowel urgency. Eligible patients complete an online survey to determine qualification, and participants receive medical support and possible travel stipends during the study. The company monetizes through research contracts and funding tied to the investigational device trial.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases like Crohn's disease and ulcerative colitis, which include medications and surgery, often have limitations and may not provide adequate relief for all patients. Many individuals with inflammatory bowel disease (IBD) still experience disruptions to their daily life and well-being despite available therapies.
Solution
Boomerang Medical is developing a bioelectronic neuromodulation device designed to offer a non-pharmacological treatment option for autoimmune diseases, specifically IBD. This implantable device uses targeted nerve stimulation to modulate the nervous system and reduce inflammation associated with Crohn's disease and ulcerative colitis. The technology has received Breakthrough Device Designation from the FDA and is currently undergoing clinical trials to evaluate its safety and efficacy in patients with mild to moderate IBD, including those who have previously undergone advanced therapies. The goal is to provide physicians with an additional tool to manage IBD, addressing the heterogeneity of the patient population and the limitations of existing biologic and pharmaceutical treatments.
Target Audience
The primary target audience includes individuals suffering from Crohn's disease and ulcerative colitis, as well as gastroenterologists and other healthcare providers specializing in the treatment of inflammatory bowel diseases.
Features
- Implantable bioelectronic device for neuromodulation
- Targeted nerve stimulation to treat Crohn's disease and ulcerative colitis
- Designed for patients with mild to moderate IBD
- Suitable for patients who have previously undergone advanced therapies
- Currently undergoing FDA-approved clinical trials